RECRUITINGPhase 2 / Phase 3INTERVENTIONAL

Study of Cannabidiol in Sanfilippo Syndrome

Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Effects of Cannabidiol on Neurobehavioral and Function Outcomes in Sanfilippo Syndrome

About This Trial

The goal of this clinical trial is to test cannabidiol in Sanfilippo syndrome. The main questions it aims to answer are: 1) determine the safety of cannabidiol in Sanfilippo syndrome, and 2) explore the efficacy of cannabidiol in treating the neurobehavioral symptoms and functional outcomes of Sanfilippo syndrome. Each participant's caregiver will be asked to complete surveys related to the participant's behavior, mood, sleep, stooling, pain, and caregiver stress intermittently throughout the study. All participants will be enrolled into one of two cohorts based on enrollment order: 1. Sentinel Safety Cohort (first 5 participants) - all participants treated with Epidiolex (cannabidiol) 2. Controlled Cohort (next 30 participants) - participants randomized 1:1 (equal chance) to start treatment with Epidiolex (cannabidiol) or placebo for 16 weeks, followed by an 8-week washout period (no treatment). Participants then switch to the opposite treatment group for 16 weeks followed by all participants treated for 52 weeks with Epidiolex (cannabidiol).

Who May Be Eligible (Plain English)

Who May Qualify: - MPS III diagnosis confirmed by genetic testing - ≥ 4 years of age - Patient or parent/legal guardian is able and willing to provide willing to sign a consent form. For patients 7 to 16 years of age, assent must also be provided when cognitively possible. - If taking any of the following, no dose changes for the last 8 weeks: 1. Anakinra 2. Fluoxetine 3. Probiotic supplement - One of the following criteria are met: 1. Previous participation in a gene/cell therapy or enzyme restorative clinical trial. 2. Previously ineligible to participate in a gene/cell therapy or enzyme restorative clinical trial due to advanced disease state. 3. Functional age, as measured by the Vineland, is ≤ 0.5 chronological age Who Should NOT Join This Trial: Equitable selection will be used when choosing participants. An individual who meets any of the following criteria will be excluded from participation in this study: - Mutation known to cause slowly progressive disease - Taken any form of cannabis, including cannabidiol, in the last 8 weeks - Currently enrolled in another ongoing clinical trial - Concomitant use of any of the following therapies: - Rifampin - Diazepam (except for intermittent use as needed for treatment of a prolonged seizure episode) - Clobazam - Stiripentol - Everolimus, sirolimus, tacrolimus - Digoxin - Valproate - Recreational or medical Tetrahydrocannabinol (THC) or synthetic cannabinoid medications (including Sativex) within the last three months - Felbamate (if taking for less than one year) - Non-pharmacological therapies (e.g. ketogenic diet) must be stable for up to four weeks prior to enrollment - Clinical evidence of liver disease or liver injury as indicated by the presence of abnormal tests (AST or ALT \&gt; 2 x ULN; Bilirubin \&gt; 2 x ULN) - Known hypersensitivity to any components of Epidiolex (cannabidiol) - Pregnant or lactating women ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * MPS III diagnosis confirmed by genetic testing * ≥ 4 years of age * Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 16 years of age, assent must also be provided when cognitively possible. * If taking any of the following, no dose changes for the last 8 weeks: 1. Anakinra 2. Fluoxetine 3. Probiotic supplement * One of the following criteria are met: 1. Previous participation in a gene/cell therapy or enzyme restorative clinical trial. 2. Previously ineligible to participate in a gene/cell therapy or enzyme restorative clinical trial due to advanced disease state. 3. Functional age, as measured by the Vineland, is ≤ 0.5 chronological age Exclusion Criteria: Equitable selection will be used when choosing participants. An individual who meets any of the following criteria will be excluded from participation in this study: * Mutation known to cause slowly progressive disease * Taken any form of cannabis, including cannabidiol, in the last 8 weeks * Currently enrolled in another ongoing clinical trial * Concomitant use of any of the following therapies: * Rifampin * Diazepam (except for intermittent use as needed for treatment of a prolonged seizure episode) * Clobazam * Stiripentol * Everolimus, sirolimus, tacrolimus * Digoxin * Valproate * Recreational or medical Tetrahydrocannabinol (THC) or synthetic cannabinoid medications (including Sativex) within the last three months * Felbamate (if taking for less than one year) * Non-pharmacological therapies (e.g. ketogenic diet) must be stable for up to four weeks prior to enrollment * Clinical evidence of liver disease or liver injury as indicated by the presence of abnormal tests (AST or ALT \&gt; 2 x ULN; Bilirubin \&gt; 2 x ULN) * Known hypersensitivity to any components of Epidiolex (cannabidiol) * Pregnant or lactating women * Any other social or medical condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study

Treatments Being Tested

DRUG

Epidiolex

Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.

DRUG

Placebo

Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring

Locations (1)

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance, California, United States